Biostem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wou… Read more
Biostem Technologies Inc (BSEM) - Total Liabilities
Latest total liabilities as of September 2025: $12.38 Million USD
Based on the latest financial reports, Biostem Technologies Inc (BSEM) has total liabilities worth $12.38 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biostem Technologies Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Biostem Technologies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biostem Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Biostem Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KEPPEL (KEP1.SG)
STU:KEP1
|
Germany | €15.82 Billion |
|
HARMONIC (HMC.SG)
STU:HMC
|
Germany | €330.92 Million |
|
Life & Banc Split Corp
TO:LBS
|
Canada | CA$484.07 Million |
|
PARROT (P2W.SG)
STU:P2W
|
Germany | €32.07 Million |
|
Applied Nutrition Plc
LSE:APN
|
UK | GBX20.70 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Biostem Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biostem Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biostem Technologies Inc (1999–2024)
The table below shows the annual total liabilities of Biostem Technologies Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $99.50 Million | +540.12% |
| 2023-12-31 | $15.54 Million | +109.59% |
| 2022-12-31 | $7.42 Million | -12.39% |
| 2021-12-31 | $8.47 Million | +1.98% |
| 2020-12-31 | $8.30 Million | +17.07% |
| 2019-12-31 | $7.09 Million | +18.72% |
| 2018-12-31 | $5.97 Million | +280.48% |
| 2017-12-31 | $1.57 Million | -30.45% |
| 2016-12-31 | $2.26 Million | +74.69% |
| 2015-12-31 | $1.29 Million | +1846.79% |
| 2014-12-31 | $66.36K | -99.17% |
| 1999-12-31 | $7.96 Million | -- |